PedAM
Pediatric Disease Annotations & Medicines
| Disease | multiple sclerosis |
| Symptom | C0235946|cortical atrophy |
| Sentences | 6 |
| PubMedID- 21228025 | Objective: to measure the effects of disease-modifying drugs (dmds) on the development of cortical lesions (cl) and cortical atrophy in patients with relapsing-remitting multiple sclerosis (rrms). |
| PubMedID- 23576622 | Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study. |
| PubMedID- 25583833 | What drives mri-measured cortical atrophy in multiple sclerosis. |
| PubMedID- 26170642 | Sc ifnβ1a was estimated to prevent 0.50 relapses and save 23 relapse-free days per patient, resulting in greater health benefits over 4 years than im ifnβ1a.90 calabrese et al compared the effects of im ifnβ1a and sc ifnβ1a on the development of cortical lesions and cortical atrophy in patients with relapsing–remitting multiple sclerosis. |
| PubMedID- 20385911 | Relationship of cortical atrophy to fatigue in patients with multiple sclerosis. |
| PubMedID- 25591534 | cortical atrophy in multiple sclerosis. |
Page: 1